Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q96DP5
UPID:
FMT_HUMAN
Alternative names:
-
Alternative UPACC:
Q96DP5; B7Z734
Background:
Methionyl-tRNA formyltransferase, mitochondrial, encoded by the gene with accession Q96DP5, plays a pivotal role in mitochondrial protein synthesis. It is responsible for the formylation of methionyl-tRNA, a critical step in the initiation of translation. This enzyme's activity is essential for mitochondrial function and energy production.
Therapeutic significance:
The enzyme is linked to Combined oxidative phosphorylation deficiency 15 and Mitochondrial complex I deficiency, nuclear type 27. These disorders manifest with neurological and muscular symptoms, underscoring the enzyme's potential as a target for therapeutic intervention. Understanding the role of Methionyl-tRNA formyltransferase, mitochondrial could open doors to potential therapeutic strategies.